Kaiser Peter
Chief Development Officer
Kaiser Peter has filed 7 SEC Form 4 filings (7 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Oct 6, 2026.
On the most recent filing, Kaiser Peter is listed as Chief Development Officer at OCULAR THERAPEUTIX, INC. Inside the rolling window, Kaiser Peter reported no open-market purchases and 5 open-market sales totaling $187K in OCUL. The largest disclosed transaction in the window is a sale of 9,990 OCUL shares on Oct 2, 2026, worth $70K.
Companies traded
Other insiders at OCUL
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$187K
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Oct 2, 2025 | OCUL | Sale | $106K |
Frequently asked questions
How many SEC Form 4 filings has Kaiser Peter made?
Kaiser Peter has filed 7 SEC Form 4 filings (7 transaction rows) across 1 company since 2025.
Which companies does Kaiser Peter trade?
Kaiser Peter has filed SEC Form 4 disclosures for 1 company, including OCUL.
When was Kaiser Peter's most recent SEC Form 4 filing?
Kaiser Peter's most recent SEC Form 4 filing on Tracefour is dated Oct 6, 2026.
What is Kaiser Peter's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Kaiser Peter is listed as Chief Development Officer.
What is Kaiser Peter's total buy and sell value in the current window?
Inside the rolling retention window, Kaiser Peter bought $0 and sold $187K based on SEC Form 4 filings.
What was Kaiser Peter's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 9,990 OCUL shares on 2026-10-02, worth $70K, per SEC Form 4 filings.